A meta-analysis of efficacy and safety of aripiprazole in adult and pediatric bipolar disorder in randomized controlled trials and observational studies

Journal of Affective Disorders

Volumn 191, Issue , 2016, Pages 187-208

  Meduri, Martina ^a   Gregoraci, Giorgia ^a   Baglivo, Valentina ^a   Balestrieri, Matteo ^a   Isola, Miriam ^a   Brambilla, Paolo ^b,c  

^a UNIVERSITY OF UDINE   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c UNIVERSITY OF TEXAS   (United States)

Author keywords

Akathisia; Extrapyramidal symptoms; Gastroenteric symptoms; Haloperidol; Hyperprolactinemia; Lithium; Safety; Sedation; Weight gain

Indexed keywords

ARIPIPRAZOLE; PROLACTIN; NEUROLEPTIC AGENT;

AKATHISIA; ARTICLE; BIPOLAR DISORDER; DRUG EFFICACY; DRUG SAFETY; EXTRAPYRAMIDAL SYMPTOM; HUMAN; HYPERPROLACTINEMIA; MANIA; MIXED MANIA AND DEPRESSION; OBSERVATIONAL STUDY; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SEDATION; SIDE EFFECT; WEIGHT GAIN; YOUNG MANIA RATING SCALE; ADOLESCENT; ADULT; AGED; AKATHISIA, DRUG-INDUCED; CHEMICALLY INDUCED; CHILD; EXTRAPYRAMIDAL SYNDROME; GASTROINTESTINAL DISEASE; MALE; META ANALYSIS; MIDDLE AGED; TREATMENT OUTCOME; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AKATHISIA, DRUG-INDUCED; ANTIPSYCHOTIC AGENTS; ARIPIPRAZOLE; BASAL GANGLIA DISEASES; BIPOLAR DISORDER; CHILD; GASTROINTESTINAL DISEASES; HUMANS; HYPERPROLACTINEMIA; MALE; MIDDLE AGED; OBSERVATIONAL STUDIES AS TOPIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME; WEIGHT GAIN; YOUNG ADULT;

EID: 84949035164     PISSN: 01650327     EISSN: 15732517     Source Type: Journal    
DOI: 10.1016/j.jad.2015.11.033     Document Type: Article

References (64)

1. K.J. Aitchison, M. Bienroth, J. Cookson, and et al. A UK consensus on the administration of aripiprazole for the treatment of mania J. Psychopharmacol. 23 2009 231 240
2. N.B. Almandil, Y. Liu, M.L. Murray, F.M. Besag, K.J. Aitchison, and I.C. Wong Weight gain and other metabolic adverse effects associated with atypical antipsychotic treatment of children and adolescents: a systematic review and meta-analysis Paediatr. Drugs 15 2013 139 150
3. A. Anglemyer, H.T. Horvath, and L. Bero Healthcare outcomes assessed with observational study designs compared with those assessed in randomized trials Cochrane Database Syst. Rev. 4 2014 46 Art. No.: MR000034, 10.1002/14651858.MR000034.pub2
4. B. Arbaizar, T. Dierssen-Sotos, I. Gómez-Acebo, and J. Llorca Aripiprazole in major depression and mania: meta-analyses of randomized placebo-controlled trials Gen. Hosp. Psychiatry 31 2009 478 483
5. C. Barbui, A. Cipriani, P. Brambilla, and M. Hotopf Which bias in antidepressant drug trials? J. Clin. Psychopharmacol. 24 2004 126 130
6. Biederman J., Mick E., Spencer T., Doyle R., Joshi G., Hammerness P., Kotarski M., Aleardi M. and Wozniak J., An open-label trial of aripiprazole monotherapy in children and adolescents with bipolar disorder, CNS Spectr. 12, 2007, 683-689
7. M. Borenstein, L.V. Hedges, J.P.T. Higgins, and H.R. Rothstein Introduction to Meta-Analysis 2009 John Wiley & Sons Chichester, UK Chapter 40
8. P. Brambilla, F. Barale, and J.C. Soares Perspectives on the use of anticonvulsants in the treatment of bipolar disorder Int. J. Neuropsychopharmacol. 4 2001 421 446
9. P. Brambilla, F. Barale, and J.C. Soares Atypical antipsychotics and mood stabilization in bipolar disorder Psychopharmacology 166 2003 315 332
10. P. Brambilla, F. Barale, E. Caverzasi, G. Tognoni, and C. Barbui Clozapine-treated subjects with resistant schizophrenia: a systematic review of experimental and observational studies Int. Clin. Psychopharmacol. 17 2002 189 195
11. R. Brown, M.J. Taylor, and J. Geddes Aripiprazole alone or in combination for acute mania Cochrane Database Syst. Rev. 12 2013 CD005000
12. K.D. Burris, T.F. Molski, C. Xu, E. Ryan, K. Tottori, T. Kikuchi, F.D. Yocca, and P.B. Molinoff Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors J. Pharmacol. Exp. Ther. 302 2002 381 389
13. A. Cipriani, C. Barbui, G. Salanti, J. Rendell, R. Brown, S. Stockton, M. Purgato, L.M. Spineli, G.M. Goodwin, and J.R. Geddes Comparative efficacy and acceptability of antimanic drugs in acute mania: a multiple-treatments meta-analysis Lancet 378 2011 1306 1315
14. C.U. Correll, P. Manu, V. Olshanskiy, B. Napolitano, J.M. Kane, and A.K. Malhotra Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents JAMA 302 2009 1765 1773
15. N. Craddock, and P. Sklar Genetics of bipolar disorder Lancet 381 2013 1654 1662
16. P. De Fazio, P. Girardi, G. Maina, M.C. Mauri, M. Mauri, P. Monteleone, G.I. Perini, G. Perugi, and A. Rossi Aripiprazole in acute mania and long-term treatment of bipolar disorder: a critical review by an Italian working group Clin. Drug Investig. 30 2010 827 841
17. Dunn R.T., Stan V.A. and Chriki L.S., A prospective, open-label study of Aripiprazole mono- and adjunctive treatment in acute bipolar depression, J. Affect. Disord. 110, 2008, 70-74
18. El Mallakh R.S., Vieta E., Rollin L., Marcus R., Carson W.H. and McQuade R., A comparison of two fixed doses of aripiprazole with placebo in acutely relapsed, hospitalized patients with bipolar disorder I (manic or mixed) in subpopulations (CN138-007), Eur. Neuropsychopharmacol. 20, 2010, 776-783
19. R.S. El-Mallakh, R. Marcus, C. Baudelet, R. McQuade, W.H. Carson, and R. Owen A 40-week double-blind aripiprazole versus lithium follow-up of a 12-week acute phase study (total 52 weeks) in bipolar I disorder J. Affect. Disord. 136 2012 258 266
20. Findling R.L., Nyilas M., Forbes R.A., McQuade R.D., Jin N., Iwamoto T., Ivanova S., Carson W.H. and Chang K., Acute treatment of pediatric bipolar I disorder, manic or mixed episode, with aripiprazole: a randomized, double-blind, placebo-controlled study, J. Clin. Psychiatry 70, 2009, 1441-1451
21. K.N. Fountoulakis, and E. Vieta Efficacy and safety of aripiprazole in the treatment of bipolar disorder: a systematic review Ann. Gen. Psychiatry 8 2009 16
22. K.N. Fountoulakis, E. Vieta, and F. Schmidt Aripiprazole monotherapy in the treatment of bipolar disorder: a meta-analysis J. Affect. Disord. 133 2011 361 370
23. K.N. Fountoulakis, X. Gonda, E. Vieta, and F. Schmidt Treatment of psychotic symptoms in bipolar disorder with aripiprazole monotherapy: a meta-analysis Ann. Gen. Psychiatry 8 2009 27
24. T.A. Furukawa, C. Barbui, A. Cipriani, P. Brambilla, and N. Watanabe Imputing missing standard deviations in meta-analyses can provide accurate results J. Clin. Epidemiol. 59 2006 7 10
25. P.J. Goodnick, and J.M. Jerry Aripiprazole: profile on efficacy and safety Expert Opin. Pharmacother. 3 2002 1773 1781
26. G.M. Goodwin, I. Anderson, C. Arango, C.L. Bowden, C. Henry, P.B. Mitchell, W.A. Nolen, E. Vieta, and H.U. Wittchen ECNP consensus meeting. Bipolar depression. Nice, March 2007 Eur. Neuropsychopharmacol. 18 2008 535 549
27. J.P.T. Higgins, and S. Green Cochrane Handbook for Systematic Reviews of Interventions 2011 The Cochrane Collaboration United Kingdom Version 5.1.0 (updated March 2011). Available from: < www.cochrane-handbook.org >
28. J.P.T. Higgins, I.R. White, and A.M. Wood Imputation methods for missing outcome data in meta-analysis of clinical trials Clin. Trials 5 3 2008 225 239
29. Jeong H.G., Lee M.S., Ko Y.H., Han C. and Jung I.K., Combination treatment with aripiprazole and valproic acid for acute mania: an 8-week, single-blind, randomized controlled trial, Clin. Neuropharmacol. 35, 2012, 97-102
30. Kanba S., Kawasaki H., Ishigooka J., Sakamoto K., Kinoshita T. and Kuroki T., A placebo-controlled, double-blind study of the efficacy and safety of aripiprazole for the treatment of acute manic or mixed episodes in Asian patients with bipolar I disorder (the AMAZE study), World J. Biol. Psychiatry 15, 2012, 113-121
31. Keck P.E., Jr., Marcus R., Tourkodimitris S., Ali M., Liebeskind A., Saha A. and Ingenito G., A placebo-controlled, double-blind study of the efficacy and safety of aripiprazole in patients with acute bipolar mania, Am. J. Psychiatry 160, 2003, 1651-1658
32. Keck P.E., Orsulak P.J., Cutler A.J., Sanchez R., Torbeyns A., Marcus R.N., McQuade R.D. and Carson W.H., Aripiprazole monotherapy in the treatment of acute bipolar I mania: a randomized, double-blind, placebo- and lithium-controlled study, J. Affect. Disord. 112, 2009, 36-49
33. D.E. Kemp, J.R. Calabrese, J.M. Eudicone, S. Ganocy, Q.V. Tran, R.D. McQuade, R.N. Marcus, E. Vester-Blokland, R. Owen, and B.X. Carlson Predictive value of early improvement in bipolar depression trials: a post-hoc pooled analysis of two 8-week aripiprazole studies Psychopharmacol. Bull. 43 2010 5 27
34. Marcus R., Khan A., Rollin L., Morris B., Timko K., Carson W. and Sanchez R., Efficacy of aripiprazole adjunctive to lithium or valproate in the long-term treatment of patients with bipolar I disorder with an inadequate response to lithium or valproate monotherapy: a multicenter, double-blind, randomized study, Bipolar Disord. 13, 2011, 133-144 (CN 138-189)
35. McElroy S.L., Suppes T., Frye M.A., Altshuler L.L., Stanford K., Martens B., Leverich G.S., Post R.M. and Keck P.E., Jr., Open-label aripiprazole in the treatment of acute bipolar depression: a prospective pilot trial, J. Affect. Disord. 101, 2007, 275-281
36. R.S. McIntyre, H.O. Woldeyohannes, B.S. Yasgur, J.K. Soczynska, A. Miranda, and J.Z. Konarski Maintenance treatment in bipolar disorder: a focus on aripiprazole Expert Rev. Neurother. 7 2007 919 925
37. R.S. McIntyre, S.L. McElroy, J.M. Eudicone, R.A. Forbes, B.X. Carlson, and R.A. Baker A 52-week, double-blind evaluation of the metabolic effects of aripiprazole and lithium in bipolar I disorder Prim. Care Companion CNS Disord. 13 6 2011
38. K. McKeage Aripiprazole: a review of its use in the treatment of manic episodes in adolescents with bipolar I disorder CNS Drugs 28 2014 171 183
39. M.F. Moro, and M.G. Carta Evaluating aripiprazole as a potential bipolar disorder therapy for adults Expert Opin. Investig. Drugs 23 2014 1713 1730
40. NCT00223496, Bristol-Myers Squibb, 2013. 12-Week Open Label Treatment of Refractory Bipolar Depression, Clinical Trials Results Bristol-Myers Squibb. < http://ctr.bms.com >.
41. NCT00592683, Massachusetts General Hospital, 2012. Omega-3 Fatty Acid Adjunctive to Open-Label Aripiprazole for the Treatment of Bipolar Disorder in Children and Adolescents.
42. NCT00665366, 2013 NCT00665366, Otsuka Pharmaceutical Development & Commercialization, 2013. Study to Evaluate the Efficacy and Safety of Aripiprazole Administered With Lithium or Valproate Over 12 Weeks in the Treatment of Mania in Bipolar I Disorder.
43. NICE, Clinical Guideline 185, Issued: September 2014. Available from: < www.guidance.nice.org.uk/cg185 >.
44. R.H. Perlis, J.A. Welge, L.A. Vornik, R.M. Hirschfeld, and P.E. Keck Jr. Atypical antipsychotics in the treatment of mania: a meta-analysis of randomized, placebo-controlled trials J. Clin. Psychiatry 67 2006 509 516
45. M.L. Phillips, and D.J. Kupfer Bipolar disorder diagnosis: challenges and future directions Lancet 381 2013 1663 1671
46. Quante A., Zeugmann S., Luborzewski A., Schommer N., Langosch J., Born C., Anghelescu I. and Wolf J., Aripiprazole as adjunct to a mood stabilizer and citalopram in bipolar depression: a randomized placebo-controlled pilot study, Hum. Psychopharmacol. 25, 2010, 126-132
47. B.C. Reeves, J.J. Deeks, J.P.T. Higgins, and G.A. Wells Including nonrandomized studies J.P.T. Higgins, S. Green, Cochrane Handbook for Systematic Reviews of Interventions 2008 The Cochrane Collaboration United Kingdom Version 5.0.1 (updated September 2008). Available from: < www.cochrane-handbook.org >
48. Sachs G., Sanchez R., Marcus R., Stock E., McQuade R., Carson W., Abou-Gharbia N., Impellizzeri C., Kaplita S., Rollin L. and Iwamoto T., Aripiprazole in the treatment of acute manic or mixed episodes in patients with bipolar I disorder: a 3-week placebocontrolled study, J. Psychopharmacol. 20, 2006, 536-546
49. Sajatovic M., Coconcea N., Ignacio R.V., Blow F.C., Hays R.W., Cassidy K.A. and Meyer W.J., Aripiprazole therapy in 20 older adults with bipolar disorder: a 12-week, openlabel trial, J. Clin. Psychiatry 69, 2008, 41-46
50. K.K. Sayyaparaju, H. Grunze, and K.N. Fountoulakis When to start aripiprazole therapy in patients with bipolar mania Neuropsychiatr. Dis. Treat. 10 2014 459 470
51. I. Shrier, J.F. Boivin, R.J. Steele, R.W. Platt, A. Furlan, R. Kakuma, J. Brophy, and M. Rossignol Should meta-analyses of interventions include observational studies in addition to randomized controlled trials? A critical examination of underlying principles Am. J. Epidemiol. 166 2007 1203 1209
52. T.A. Stern, M. Fava, T.E. Wilens, and J.F. Rosenbaum Massachusetts General Hospital Comprehensive Clinical Psychiatry 2nd Edition 2015 Elsevier Philadelphia
53. Thase M.E., Jonas A., Khan A., Bowden C.L., Wu X., McQuade R.D., Carson W.H., Marcus R.N. and Owen R., Aripiprazole monotherapy in nonpsychotic bipolar I depression: results of 2 randomized, placebo-controlled studies, J. Clin. Psychopharmacol. 28, 2008, 13-20 (CN138-096 and CN138-146)
54. M. Tohen, F. Zhang, C.C. Taylor, P. Burns, C. Zarate, T. Sanger, and G. Tollefson A meta-analysis of the use of typical antipsychotic agents in bipolar disorder J. Affect. Disord. 65 2001 85 93
55. Tramontina S., Zeni C.P., Ketzer C.R., Pheula G.F., Narvaez J. and Rohde L.A., Aripiprazole in children and dolescents with bipolar disorder comorbid with attention-deficit/hyperactivity disorder: a pilot randomized clinical trial, J. Clin. Psychiatry 70, 2009, 756-764
56. E. Vieta, and M. Valentí Pharmacological management of bipolar depression: acute treatment, maintenance, and prophylaxis CNS Drugs 27 2013 515 529
57. Vieta E., T'joen C., McQuade R.D., Carson W.H., Jr, Marcus R.N., Sanchez R., Owen R. and Nameche L., Efficacy of adjunctive aripiprazole to either valproate or lithium in bipolar mania patients partially nonresponsive to valproate/lithium monotherapy: a placebo-controlled study, Am. J. Psychiatry 165, 2008, 1316-1325
58. Vieta E., Bourin M., Sanchez R., Marcus R., Stock E., McQuade R., Carson W., Abou- Gharbia N., Swanink R. and Iwamoto T., 2005. Effectiveness of aripiprazole v. haloperidol in acute bipolar mania: double-blind, randomised, comparative 12-week trial, Br. J. Psychiatry 187, 2005, 235-242
59. E. Von Elm, D.G. Altman, M. Egger, S.J. Pocock, P.C. Gøtzsche, and J.P. Vandenbroucke Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies BMJ 335 2007 806 808
60. M.M. Weissman, R.C. Bland, G.J. Canino, C. Faravelli, S. Greenwald, H.G. Hwu, P.R. Joyce, E.G. Karam, C.K. Lee, J. Lellouch, J.P. Lépine, S.C. Newman, M. Rubio-Stipec, J.E. Wells, P.J. Wickramaratne, H. Wittchen, and E.K. Yeh Cross-national epidemiology of major depression and bipolar disorder JAMA 276 1996 293 299
61. L.N. Yatham, S.H. Kennedy, A. Schaffer, S.V. Parikh, S. Beaulieu, C. O'Donovan, G. MacQueen, R.S. McIntyre, V. Sharma, A. Ravindran, L.T. Young, A.H. Young, M. Alda, R. Milev, E. Vieta, J.R. Calabrese, M. Berk, K. Ha, and F. Kapczinski Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2009 Bipolar Disord. 11 2009 225 255
62. L.N. Yatham, S.H. Kennedy, S.V. Parikh, A. Schaffer, S. Beaulieu, M. Alda, C. O'Donovan, G. Macqueen, R.S. McIntyre, V. Sharma, A. Ravindran, L.T. Young, R. Milev, D.J. Bond, B.N. Frey, B.I. Goldstein, B. Lafer, B. Birmaher, K. Ha, W.A. Nolen, and M. Berk Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2013 Bipolar Disord. 15 2013 1 44
63. Young A.H., Oren D.A., Lowy A., McQuade R.D., Marcus R.N., Carson W.H., Spiller N.H., Torbeyns A.F. and Sanchez R., 2009. Aripiprazole monotherapy in acute mania: 12-week randomised placebo- and haloperidol-controlled study, Br. J. Psychiatry 194, 2009, 40-48
64. M. Zwahlen, A. Renehan, and M. Egger Meta-analysis in medical research: potentials and limitations Urol. Oncol. 26 2008 320 329